We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Read MoreHide Full Article
Key Takeaways
Tempus AI now expects 2025 revenues to be about $1.26B, up from the prior $1.25B forecast.
TEM's Q2 revenues jumped 89.6% year over year, led by 115.3% growth in genomics sales.
TEM's new oncology tools, Tempus Next and Tempus xM, supported the revenue outlook revision.
Recently, Tempus AI (TEM - Free Report) updated its sales guidance for 2025. It did so for the second time within six months, backed by a strong second-quarter performance. Full-year revenues are now expected to be approximately $1.26 billion (earlier $1.25 billion), indicating nearly 82% annual growth.
The company reported second-quarter revenues of $314.6 million, up 89.6% on a year-over-year basis. In the quarter, the Genomics business contributed $193.8 million to revenues, reflecting 115.3% growth year over year. This growth was driven by accelerating volume growth (up 26% year over year) in oncology.
The gross profit totaled $195 million, up a huge 158.3% from the year-ago quarter’s level. The adjusted gross margin expanded 1649 bps to 62% despite a 32.2% rise in the cost of revenues. Additionally, Tempus AI experienced another quarter of sequential improvement in adjusted EBITDA, which went from a negative $16 million last quarter to a negative $5.6 million this quarter. This improvement made the company expect a positive adjusted EBITDA of $5 million in 2025.
Tempus AI extended Tempus Next care pathway intelligence platform into breast cancer, furthering AI-driven decision support across oncology. Also, it introduced Tempus xM for treatment and response monitoring (TRM), a liquid biopsy assay designed to monitor immunotherapy response in patients with advanced solid tumors, providing clinicians with actionable, real-time insights. These recent developments also encouraged the company to raise its 2025 revenue guidance.
Robust Q2 Performance by TEM’s Competitors
Exact Sciences Corporation (EXAS - Free Report) delivered a record 1.3 million test results to patients, accelerated revenue growth to 16% and generated an all-time high adjusted EBITDA of $138 million. Operationally, Screening revenues climbed 18% to $628 million on robust Cologuard adoption, and Precision Oncology revenues rose 9% on international uptake of Oncotype DX. Reflecting this momentum, management raised its 2025 revenue guidance to $3.13-$3.17 billion (from $3.07-$3.12 billion) and adjusted EBITDA guidance to $455-$475 million (from $425-$455 million).
Guardant Health (GH - Free Report) delivered a strong second-quarter performance, with revenues up 31% year over year to $232.2 million, driven by robust performance across the oncology, screening and biopharma and data businesses. Oncology volumes increased 30% year over year to 64,000 tests, with the majority of growth driven by Guardant360 Liquid. The company saw gross profit of $153.8 million, up 44% year over year. Based on the performance, GH raised its full-year 2025 revenue guidance to $915-$925 million from $880-$890 million, implying growth of 24-25% year over year.
TEM Stock Outperforms Industry & Benchmark
In the past year, Tempus AI shares have surged 42.6%, outperforming the industry’s 23.4% growth and the S&P 500 composite’s 18.3% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.32X compared with the industry average of 5.57X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's projected loss per share has improved 2.9% for 2025 and 12% for 2026.
Image: Bigstock
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Key Takeaways
Recently, Tempus AI (TEM - Free Report) updated its sales guidance for 2025. It did so for the second time within six months, backed by a strong second-quarter performance. Full-year revenues are now expected to be approximately $1.26 billion (earlier $1.25 billion), indicating nearly 82% annual growth.
The company reported second-quarter revenues of $314.6 million, up 89.6% on a year-over-year basis. In the quarter, the Genomics business contributed $193.8 million to revenues, reflecting 115.3% growth year over year. This growth was driven by accelerating volume growth (up 26% year over year) in oncology.
The gross profit totaled $195 million, up a huge 158.3% from the year-ago quarter’s level. The adjusted gross margin expanded 1649 bps to 62% despite a 32.2% rise in the cost of revenues. Additionally, Tempus AI experienced another quarter of sequential improvement in adjusted EBITDA, which went from a negative $16 million last quarter to a negative $5.6 million this quarter. This improvement made the company expect a positive adjusted EBITDA of $5 million in 2025.
Tempus AI extended Tempus Next care pathway intelligence platform into breast cancer, furthering AI-driven decision support across oncology. Also, it introduced Tempus xM for treatment and response monitoring (TRM), a liquid biopsy assay designed to monitor immunotherapy response in patients with advanced solid tumors, providing clinicians with actionable, real-time insights. These recent developments also encouraged the company to raise its 2025 revenue guidance.
Robust Q2 Performance by TEM’s Competitors
Exact Sciences Corporation (EXAS - Free Report) delivered a record 1.3 million test results to patients, accelerated revenue growth to 16% and generated an all-time high adjusted EBITDA of $138 million. Operationally, Screening revenues climbed 18% to $628 million on robust Cologuard adoption, and Precision Oncology revenues rose 9% on international uptake of Oncotype DX. Reflecting this momentum, management raised its 2025 revenue guidance to $3.13-$3.17 billion (from $3.07-$3.12 billion) and adjusted EBITDA guidance to $455-$475 million (from $425-$455 million).
Guardant Health (GH - Free Report) delivered a strong second-quarter performance, with revenues up 31% year over year to $232.2 million, driven by robust performance across the oncology, screening and biopharma and data businesses. Oncology volumes increased 30% year over year to 64,000 tests, with the majority of growth driven by Guardant360 Liquid. The company saw gross profit of $153.8 million, up 44% year over year. Based on the performance, GH raised its full-year 2025 revenue guidance to $915-$925 million from $880-$890 million, implying growth of 24-25% year over year.
TEM Stock Outperforms Industry & Benchmark
In the past year, Tempus AI shares have surged 42.6%, outperforming the industry’s 23.4% growth and the S&P 500 composite’s 18.3% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.32X compared with the industry average of 5.57X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's projected loss per share has improved 2.9% for 2025 and 12% for 2026.
Image Source: Zacks Investment Research
TEM stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.